source
- Alnylam faces slowdown in Amvuttra sales, putting its growth ambitions at riskAlnylam’s market narrative has long hinged on the performance of its cardiomyopathy drug Amvuttra. The company once hoped the therapy could lift its valuation toward the $100 billion range. Recent…
- Blackstone pledges up to $1.5 billion to fund Pfizer's obesity drug berobenatide developmentBlackstone Life Sciences has agreed to provide up to $1.5 billion to support the research and development of Pfizer's obesity candidate, berobenatide, which originated from the former Metsera progr…